Blood-based Biomarkers for Early Alzheimer's Disease Screening

Peking University First Hospital1 site in 1 country180 target enrollmentJune 18, 2024

ConditionsAlzheimer's Disease Blood Biomarkers

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Alzheimer's Disease
Sponsor: Peking University First Hospital
Enrollment: 180
Locations: 1
Primary Endpoint: Evaluate the diagnostic accuracy of blood biomarkers of Aβ42, Aβ40, Aβ42/Aβ40, P-Tau181, P-Tau217, GFAP and NfL.
Status: Recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The goal of this observational study is to estimate the screen performance of blood biomarkers of interest (Aβ40 and Aβ42, P-Tau181, P-Tau217, GFAP and NfL) in patients with Alzheimer's disease (AD), mild cognitive impairment due to AD, and cognitively normal individuals. The main questions it aims to answer are:

to identify core blood biomarker suitable for early screening of AD.
to establish a comprehensive model for the early identification of AD.

Registry

clinicaltrials.gov

Start Date

June 18, 2024

End Date

March 26, 2026

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

Peking University First Hospital

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Age ≥ 50 years;
•AD (meets the 2011 NIA-AA AD diagnostic criteria), or MCI (meets the 2004 Peterson MCI diagnostic criteria), or cognitively normal subjects;
•Signed informed consent form.